Reactivity of pulmonary circulation and right ventricle function to inhaled nitric oxide in systemic sclerosis patients

Wojciech Plazak · Krzysztof Gryga · Jan Sznajd · Joanna Wilisowska · Ewa Czarnobilska · Grzegorz Goncerz · Piotr Podolec · Jacek Musial

Received: 6 November 2010 / Revised: 5 April 2011 / Accepted: 31 May 2011 / Published online: 14 June 2011
© The Author(s) 2011. This article is published with open access at Springerlink.com

Abstract Systemic sclerosis (SSc) is complicated by pulmonary hypertension and right ventricle (RV) failure in approximately 10% of the patients. Factors influencing the reactivity of pulmonary circulation to vasodilators are not established, while the examination of vasoreactivity is important in determining the treatment, because systemic administration of oral vasodilators can induce severe adverse events in nonresponders. The mechanism of RV failure in SSc is unclear and may result either from increased RV afterload or intrinsic myocardial disease. The aim of the study was to assess the reactivity of pulmonary circulation to inhaled nitric oxide (iNO) and to evaluate its influence on RV function in SSc patients with elevated right ventricle systolic pressure (RVSP). In 60 SSc patients aged 24–73 (58 females, two males; 33 patients with limited SSc and 27 with diffuse SSc), echocardiographic examination with tissue Doppler echocardiography (TDE) was performed. RV function was measured by systolic (S) and early diastolic (E) velocity of tricuspid annulus by TDE. In patients with RVSP >45 mmHg, the reactivity of pulmonary circulation was assessed by iNO test. High-resolution computerized tomography (HRCT) was performed to assess the extent of pulmonary fibrosis. Of 14 SSc subjects with elevated RVSP (13 females, one male; RVSP 47–62 mmHg), positive reaction to iNO was observed in five (RVSP decreased from 51.6±3.7 to 32.2±2.3 mmHg); nine patients were not reactive (RVSP 53.5±5.7 mmHg before iNO vs. 49.6±6.7 mmHg). RV systolic function was decreased in patients with elevated RVSP as compared to the patients with normal pulmonary pressure (S velocity 13.2±1.3 vs. 14.4±1.6 cm/s, respectively, p<0.05). Significant increase of RV systolic function during iNO test was found in reactive patients only (S velocity before iNO 12.8±1.2 cm/s, during iNO 14.5±1.5 cm/s, p<0.01). RVSP decrease strongly correlated with S velocity increase (r=0.95, p<0.0001). Response to iNO was found only in limited form of SSc; diffuse SSc patients showed no response. Pulmonary fibrosis on HRCT was more frequent in subjects nonreactive to iNO (67% of patients) than in the reactive group (40% of patients). The reactivity of pulmonary circulation to iNO in SSc patients with elevated RVSP was found predominantly in limited form of the disease. Pulmonary fibrosis typical for diffuse SSc was more frequent in nonreactive subjects. Elevated pulmonary pressure plays an important role in RV systolic dysfunction. Pulmonary pressure decrease during iNO test leads to the improvement of RV systolic function. Therapy for right-heart failure in reactive SSc patients should be directed, if possible, at the decrease in pulmonary resistance.

Keywords Heart failure · Pulmonary circulation · Right ventricle · Systemic sclerosis
Objective and aim of the study

Systemic sclerosis (SSc) is complicated in approximately 10% of the patients by pulmonary hypertension (PH) caused mainly by an increase in pulmonary vascular resistance [1]. The prognosis of SSc–PH without pulmonary circulation-targeted therapies is particularly poor, with estimated survival rates of approximately 50% at 2 years [1]. While prostacyclin, endothelin receptor antagonists and phosphodiesterase-5 inhibitors has been shown to be partially efficacious in PH, SSc–PH remains incurable [1]. Moreover, factors influencing reactivity of pulmonary circulation to vasodilators seen in some patients [2] remain unknown [3]. Their identification may be important to make a proper choice of treatment because systemic administration of oral vasodilators can induce severe adverse events in nonresponders [4].

The second factor influencing prognosis in SSc patients is cardiac involvement. While left ventricle diastolic dysfunction plays a major role [5], recent studies based on tissue Doppler echocardiography (TDE) has also shown systolic and diastolic dysfunction involving right ventricle [6, 7]. The mechanism of right ventricle dysfunction in SSc is not completely understood: this may involve increased right ventricle afterload caused by pulmonary hypertension as well as SSc-specific fibrotic tissue accumulation in the myocardium.

The aim of the study was to assess the reactivity of pulmonary circulation to inhaled nitric oxide (iNO) and to evaluate its influence on right ventricle function in SSc patients with elevated right ventricle systolic pressure (RVSP).

Material and methods

Study group consisted of 60 consecutive SSc patients (58 females, two males) aged 24–73 (mean age 54.4 years). The diagnosis was established according to the American College of Rheumatology standards [8]. Limited SSc was diagnosed in 33 (55%) patients, and diffuse SSc in 27 (45%). Duration of the disease was 2–32 years (mean 15.5 years). Scl-70 autoantibodies were found in 42 (70%) patients, anticientromere in 16 (26.7%), and other autoantibodies (anti-fibrillarin, Ku, Ro, antimitochondrial) in 13 (21.7%). Arterial hypertension was present in four patients. Dyspnea at rest was not observed in any of the patients. The results of peripheral blood count, serum sodium, potassium, glucose, creatinine, and urinalysis were all normal. The patients were treated with (n, %): pentoxyfilline (42, 70%), calcium blockers (18, 30%), cinnarizine (10, 16.7%), nicergoline (7, 11.7%), xantinol nicotinate (10, 16.7%), bencyclane (7, 11.7%), prednisone (8, 13.3%), angiotensin-converting enzyme inhibitors (18, 30%), diosmine (13, 21.7%), ranitidine (8, 13.3%), and hydroxizine (13, 21.7%).

In all the subjects, echocardiographic examination with tissue Doppler echocardiography was performed. The data obtained from echocardiographic examination (Toshiba Apio SSA-770 Ultrasound System, Toshiba, Japan) included: diastolic and systolic dimension of left ventricle, ejection fraction of left ventricle (Simpson method), diastolic dimension of right ventricle, thickness of the left ventricle walls in diastole, E and A mitral inflow velocity, valvular pressures gradients, and regurgitation assessment. RVSP was calculated from the velocity of tricuspid regurgitant jet (V_{tr}) according to the equation RVSP = 4V_{tr} + RAPmmHg, where RAP represents right atrial pressure, estimated as 5 or 10 mmHg due to inferior vena cava and right atrium diameters. During TDE examination, the velocities of tricuspid annulus were recorded from four-chamber view during systole (S velocity) and early diastole (E velocity). Isovolumetric relaxation time (IVRT) was measured by TDE examination as the time from the end of S velocity to the onset of E velocity.

Based on right-heart catheterization studies, a gold standard for pulmonary artery pressure measurement, RVSP=47 mmHg might be used as a cut-off point for PH screening in SSc patients by means of echocardiography [9]. In our study, in patients with RVSP exceeding 45 mmHg, the reactivity of pulmonary circulation was assessed by inhaled nitric oxide test. However it is apparent that a significant proportion of the hemodynamic response to iNO occurs at concentrations below 10 ppm [4], we used the maximal dose of iNO (40 ppm) [4]. All the aforementioned echocardiographic and TDE parameters were determined in patients during the test (after 10 min of breathing NO). Positive reaction to iNO (reactive pulmonary circulation) was defined as a decrease of RVSP of more than 10 mmHg during the test. In patients with elevated RVSP, spirometry and high-resolution computerized tomography were performed to assess the extent of pulmonary involvement.

Statistical analysis was performed using Statistica Six Sigma software. All numerical data were expressed as mean values±standard deviations or as proportions. Continuous variables were compared by use of t test. Chi-square test was used to examine differences in proportions. The relationship between the pulmonary systolic pressure change and the tricuspid annulus systolic velocity change was shown by use of linear regression with 95% confidence intervals. The level for statistical significance was predetermined at p<0.05.

The study was approved by the Ethical Committee. Before the study, informed consent was obtained from each patient. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.
Results

Echocardiographic examination showed normal left ventricle dimensions (47.7±5.9 mm in diastole, 30.5±7.5 mm in systole) with normal ejection fraction (67.5±7.3%) in 58 (96.7%) SSc patients. Left ventricle was dilated (>56 mm in diastole) and ejection fraction decreased (<55%) in two (3.3%) patients. In contrast, mitral inflow E/A ratio was decreased (<1.0) in 38 (63.3%) patients, showing diastolic left ventricular dysfunction, that was present despite normal left ventricle muscle thickness (intraventricular septum diastolic thickness 8.9±1.8 mm, posterior wall diastolic thickness 8.8±1.6 mm). No signs of significant valvular disturbances were observed, excepting moderate tricuspid insufficiency in 21 (46%) patients. Right ventricle was dilated (>30 mm in parasternal view) in eight (13.3%) patients.

Among 60 examined patients, RVSP >45 mmHg was found in 14 subjects, 13 females and one male. Left ventricle dimensions and function were normal in this group. RVSP values ranged from 47 to 62 mmHg (mean 53.6±4.8 mmHg). In the remaining 46 patients, mean RVSP value was 28.2±3.7 mmHg (ranging from 20 to 36 mmHg).

The dose of iNO (40 ppm) appeared safe and did not result in systemic hypotension in any of the 14 patients in which the test was performed. Out of this group, positive reaction to iNO was observed in five patients. Their mean pulmonary systolic pressures decreased from 51.6±3.7 to 32.24±2.3 mmHg. In the remaining nine patients, pulmonary pressures did not change (53.5±5.7 mmHg before the test, 49.6±6.7 mmHg during the test; Fig. 1).

Right ventricle systolic function was decreased in patients with RVSP elevation as compared to the patients with normal pulmonary pressure (S velocity 13.2±1.3 vs. 14.4±1.6 cm/s, respectively; p<0.05), diastolic right ventricle function was comparable in both groups (E velocity 12.8±2.2 vs. 13.4±4.2 cm/s, respectively, p>0.05). During iNO test, significant increase of right ventricle systolic function was found in the group of five patients with reactive pulmonary circulation; whereas in nonreactive patients, systolic function of right ventricle remained unchanged (Fig. 2). Diastolic right ventricle function was not changed in neither group (E velocity in reactive patients 12.9±1.2 cm/s before iNO, 12.7±1.7 cm/s during iNO, E velocity in nonreactive patients 12.8±3.1 cm/s before iNO, 13.8±1.7 cm/s during iNO).

The isovolumetric relaxation time of right ventricle (normal values, <40 ms [10]) was significantly prolonged in patients with RVSP >45 mmHg as compared to patients with normal pulmonary systolic pressure (90±7.7 vs. 28±9.4 ms, respectively, p<0.001). In subjects with reactive pulmonary circulation, IVRT normalized from 87±5.7 to 27±11.4 ms during iNO test (p<0.001; Fig. 3); whereas in nonreactive, subjects remained unchanged (93±8.7 ms before iNO, 89±13.5 ms during iNO).

Strong correlation was found between the decrease in RVSP and the increase in tricuspid annulus systolic velocity (r=0.95, p<0.0001; Fig. 4).

The type of the disease strongly differentiated patients with reactive from those with nonreactive pulmonary circulation. All patients with diffuse form of systemic sclerosis did not respond to iNO. On the other hand, all but one patient with limited type of the disease were reactive (Table 1; p<0.05). Furthermore, the presence of pulmonary fibrosis on high-resolution computerized tomography (HRCT) scans was more frequent in nonreactive subjects (67% of patients) than in the reactive group (40% of...
patients, \( p < 0.05 \). The single male in this group was not reactive. Age of the patients, duration of the disease, RVSP, and spirometry results had no influence on the reactivity of pulmonary circulation to iNO (Table 1).

**Discussion**

The main finding of the study includes the influence of increased right ventricle afterload due to elevation of pulmonary artery systolic pressure on right ventricle systolic dysfunction in SSc patients. Decrease of pulmonary pressure during inhaled NO test leads to right ventricle systolic function improvement.

Pulmonary hypertension is a devastating vascular complication of a number of connective tissue diseases, first of all systemic sclerosis, where it has a dramatic impact on the clinical course and overall survival. PH and pulmonary fibrosis are the most common cause of death in patients afflicted with SSc [11]. Although remarkable advances have been made to elucidate pathogenesis of idiopathic PH and in consequence to develop disease-targeted therapies, the response to this therapy in SSc-related PH is suboptimal and survival remains poor [12]. While in diffuse SSc, PH is usually secondary to interstitial lung disease, it occurs commonly also in patients with limited form of SSc [13]. Due to clinical similarity, the results of therapeutic trials in idiopathic PH are used to

![Fig. 3](image1.png)  
**Fig. 3** Influence of iNO on right ventricle IVRT. IVRT measured by TDE represents the distance between the end of systolic S wave and the beginning of early diastolic E wave.  

- **a** In a patient with elevated pulmonary artery systolic pressure (57 mmHg), IVRT is prolonged (>100 ms).
- **b** During iNO test, pulmonary pressure decreases (32 mmHg) with IVRT normalization to <30 ms in this patient.

![Fig. 4](image2.png)  
**Fig. 4** Correlation between right ventricle systolic pressure (RVSP) decrease (\( \Delta RVSP \)) and tricuspid systolic velocity increase (\( \Delta S \)) during iNO test.
guide treatment in SSc-Ph [12]. On the other hand, SSc patient population is becoming an important study group for the evaluation of novel pulmonary vasodilator therapies. Despite the similarities between idiopathic and SSc-related PH, pathologic findings may vary reflecting different pathogenetic mechanisms.

Inhaled NO is a selective pulmonary vasodilator that acts preferentially on ventilated regions. Because it is rapidly inactivated by hemoglobin, this mode of administration produces little, if any, direct effect on the systemic vasculature. There is no ventilation-perfusion mismatching or hypotension, which often limit the use of conventional nonselective vasodilators [14]. In the present study, the dose of iNO (40 ppm) appeared safe and did not result in systemic hypotension in any patient.

We showed that the type of the disease and the presence of fibrosis on HRCT strongly differentiated patients with reactive from those with nonreactive pulmonary circulation. Pulmonary fibrosis in diffuse SSc patients leads to the persistent elevation of pulmonary artery systolic pressure. This condition makes the prognosis of the patients particularly grim [15]. The elevation of pulmonary artery pressure in limited SSc may result, among others, from vasospasm due to, e.g., decreased production of endogenous inducible NO synthase [16, 17]. Thus, the vasospasm and pulmonary resistance in limited SSc may react to iNO. This finding may help to select patients who may benefit from treatment with vasodilators. The therapy aimed at decreasing the pulmonary pressure is of utmost importance, not only in a long-term prognosis, but also in a short term, where even slight elevation of pulmonary resistance (pulmonary pressures in the upper normal range) leads to a significantly decreased exercise capacity [18].

Tissue Doppler echocardiography gives the possibility to assess systolic and diastolic right ventricle function that is not attainable with standard echocardiography [6]. Recent studies in SSc patients based on TDE showed both systolic and diastolic right ventricle dysfunction [6, 7]. We showed impaired right ventricle systolic function in the patients with elevated RVSP as compared to the patients with normal pulmonary pressure. However, in patients with reactive pulmonary circulation, a significant increase in right ventricle systolic function during iNO test was demonstrated. On the contrary, in nonreactive patients, systolic function of the right ventricle remained unchanged. A drop in pulmonary systolic pressure during iNO test highly correlated with tricuspid annulus systolic velocity increase (Fig. 4).

The IVRT of the right ventricle is a sensitive marker of pulmonary pressure elevation [10, 19]. The normalization of IVRT during iNO test confirms the decrease in pulmonary systolic pressures and improvement in RV function in reactive patients. There are few data from literature concerning the RV function improvement during iNO test. The results based on right-heart catheterization presented by Sitbone [4] confirmed increase in right ventricle stroke volume in iNO responders. With regard to the reactivity of RV function to iNO test, we may expect the improvement of RV function during the treatment focused on the decrease in pulmonary pressure [20]. It was shown that tricuspid annulus systolic velocity above 12 cm/s predicts the lower incidence of readmission to hospital and improves prognosis [7]. In SSc patients reactive to iNO, therapy of right-heart failure should then be focused on decreasing pulmonary resistance. The increase in tricuspid annulus systolic velocity >12 cm/s should be our aim while lowering pulmonary artery pressure in right-heart failure SSc patients.

**Limitations of the study**

Although the study was performed in 60 SSc patients, the main findings concerning the reactivity of pulmonary circulation to iNO are based on the examination of limited group of 14 patients with elevated pulmonary artery pressure.

|                        | Reactive | Nonreactive | p Value |
|------------------------|----------|-------------|---------|
| Age (years)            | 53.2±11.8| 57.7±3.3    | ns      |
| Gender                 | 5 (100%) females | 8 (89%) females | ns |
|                       | 0 (0%) males | 1 (11%) males |    |
| Time of the disease (years) | 4.5±1.9 | 3.5±1.4 | ns |
| Type of the disease    | 5 (100%) limited | 1 (11%) limited | <0.05 |
|                       | 0 (0%) diffuse | 8 (89%) diffuse |    |
| Right ventricle systolic pressure (mmHg) | 51.6±3.7 | 53.5±5.7 | ns |
| Spirometry–FVC (liters) | 2.71±0.9 | 2.51±0.8 | ns |
| Spirometry–FEV1 (liters) | 2.26±0.8 | 2.09±0.7 | ns |
| Pulmonary fibrosis in HRCT | 2 (40%) present | 6 (67%) present | <0.05 |
|                       | 3 (60%) absent | 3 (33%) absent |    |
systolic pressure. All measurements were performed non-invasively, without direct hemodynamic assessment. The group of patients evaluated during the study requires long-term follow up.

Conclusions

Pulmonary circulation reactive to inhaled NO was found predominantly in limited type of systemic sclerosis. The presence of pulmonary fibrosis typical for diffuse SSc was more frequent in nonreactive subjects. Increased right ventricle afterload due to elevated pulmonary artery systolic pressure is an important factor influencing right ventricle systolic dysfunction in SSc patients. Decrease of pulmonary pressure during inhaled NO test leads to right ventricle systolic function improvement. This suggests that the therapy of right-heart failure in reactive patients should be aimed if possible on the decrease in pulmonary resistance.

Acknowledgments This study was supported by a grant No N40201231/0460 from the Polish Ministry of Science and Higher Education.

Disclosures None.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Kowal-Bielecka O, Delcroix M, Vonk-Noordegraaf A et al (2008) Outcome measures in pulmonary arterial hypertension associated with systemic sclerosis. Rheumatology (Oxford) 47(supl. 5):39–41
2. Morales-Blanhir J (2004) Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 98:225–234
3. Sasahara A (2009) Pulmonary arterial hypertension in systemic sclerosis: can we predict responders for successful therapy? (editorial). J Rheumatol 36:665–666
4. Sitbon O, Brenot F, Denjean A et al (1995) Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose–response study and comparison with prostacyclin. Am J Respir Crit Care Med 151:384–389
5. Plazak W, Zabinska-Plazak E, Wojas-Pelec A et al (2002) Heart structure and function in systemic sclerosis. Eur J Dermatol 12:257–262
6. D’Andrea A, Stisi S, Bellissimo S et al (2005) Early impairment of myocardial function in systemic sclerosis: non-invasivasive assessment by Doppler myocardial and strain rate imaging. Eur J Echocardiogr 6:407–418
7. Hsiao SH, Lee CY, Chang SM et al (2006) Right heart function in scleroderma: insight from myocardial Doppler tissue imaging. J Am Soc Echocardiogr 19:507–514
8. Smolen J, Weisman M (2008) Connective tissue disorders. In: Hochberg M, Silman A, Smolen J, Weinblatt M, Weisman M (eds) Rheumatology. Mosby Elsevier, Philadelphia, pp 1205–1485
9. Hsu VM, Moreyra AE, Wilson AC et al (2008) Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 35:458–465
10. Lindqvist P, Waldenstrom A, Wikstrom G et al (2006) Right ventricular myocardial isovolumic relaxation time and pulmonary pressure. Clin Physiol Funct Imaging 26:1–8
11. Le Pavec J, Humbert M, Mouthon L et al. (2011) Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med (in press).
12. Kowal-Bielecka O, Landewe R, Avouac J et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68:620–628
13. Breit SN, Thornton SC, Penny R (1994) Lung involvement in scleroderma. Rev Clin Dermatol 12:243–252
14. Williamson DJ, Hayward C, Rogers P et al (1996) Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension. Circulation 94:477–482
15. Mathai SC, Hummers LK, Champion HC et al (2009) Survival in pulmonary hypertension associated with the sclerodrma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 60:569–577
16. Allanore Y, Borderie D, Hilliquin P et al (2001) Low levels of nitric oxide (NO) in systemic sclerosis: inducible NO synthase production is decreased in cultured peripheral blood monocyte/macrophage cells. Rheumatology (Oxford) 40:1089–1096
17. Menkes CJ, Allanore Y, Borderie D et al (2001) Inducible nitric oxide synthase expression and nitric oxide production by monocytes in systemic sclerosis. Bull Acad Natl Med 185:509–522
18. Kovacs G, Maier R, Aberer E et al (2009) Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma. Am J Respir Crit Care Med 180:881–886
19. Brechot N, Gambotti L, Lafitte S et al (2008) Usefulness of right ventricular isovolumic relaxation time in predicting systolic pulmonary artery pressure. Eur J Echocardiogr 9:547–554
20. Freyhauser H, Dumitrescu D, Bovenschulte H et al (2009) Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin Res Cardiol 98:265–267